Blalock Williams’s AbbVie ABBV Stock Holding History

Blalock Williams’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Sell	1,113 -57	-5%	-$12.3K	0.18%	114
2026 Q1	$254K	Sell	1,170 -11	-0.9%	-$2.44K	0.2%	111
2025 Q4	$270K	Sell	1,181 -40	-3%	-$9.11K	0.22%	107
2025 Q3	$283K	Buy	+1,221	New	+$249K	0.25%	96
2025 Q2	–	Sell	-986	Closed	-$207K	–	124
2025 Q1	$207K	Buy	+986	New	+$192K	0.23%	109

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Blalock Williams's ABBV Position: Q2 2026 in Review

Blalock Williams reduced its AbbVie (ABBV) stake by 4.9% in Q2 2026, selling an estimated $12.3K and leaving 1,113 shares worth $280K. The position accounts for 0.18% of the portfolio, ranked #114.

Blalock Williams first reported a position in ABBV in Q1 2025 and has held it in 5 quarters since. The position peaked at $283K in Q3 2025. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Blalock Williams held 1,113 shares of AbbVie worth $280K as of Q2 2026.
Blalock Williams sold 57 AbbVie shares in Q2 2026, an estimated $12.3K.
AbbVie made up 0.18% of Blalock Williams's portfolio in Q2 2026, its #114 holding.
Blalock Williams first reported a position in AbbVie in Q1 2025 and has held it in 5 quarters since.
Blalock Williams's AbbVie position peaked at $283K in Q3 2025.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Blalock Williams's 13F filing for Q2 2026, filed 7 Aug 2026.